FIELD: medicine, pharmaceutics.SUBSTANCE: there are offered: a pharmaceutical combination comprising an a7 nicotinic receptor agonist, which represents (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurane-2-carboxamide or a pharmaceutically acceptable salt or a solvate thereof, and at least one antipsychotic agent, wherein the mentioned combination provides a synergistic therapy of a mental disorder, the use thereof for preparing a therapeutic agent for treating or preventing the mental disorder, an appropriate method of treating, and a set comprising a package and the specified synergistic combination. What is shown is a synergistic effect of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurane-2-carboxamide in a combination with clozapine on the state of fear, or in a combination with quetiapine by a value of a start pulse (startle response and PPI).EFFECT: what is presented is a combination of alpha 7 nicotinic agonist receptors and antipsychotic agents.23 cl, 14 dwg, 1 tbl, 11 ex
COMBINATION OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS AND ANTIPSYCHOTIC AGENTS